University of Oulu

Mälkönen, T., Nuutinen, P., Hallinen, T., Soini, E., Nissinen, R., Wennerstöm, C., Rantanen, T., Hagman, J. H., Harvima, R., Höök-Nikanne, J., Ilves, T., Lintu, P., Malanin, K., Soramäki, I., Tasanen, K., Teho, A., Vähävihu, K., Itälinna, S., Leinonen, P., Sarajärvi, P., Huilaja, L., & Pasternack, R. (2022). Guselkumab Treatment Outcomes and Persistence in a Nationwide Real-world Cohort of Patients with Plaque Psoriasis. Acta Dermato-Venereologica, 102, adv00631.

Guselkumab treatment outcomes and persistence in a nationwide real-world cohort of patients with plaque psoriasis

Saved in:
Author: Mälkönen, Tarja1; Nuutinen, Pauliina1; Hallinen, Taru2;
Organizations: 1Skin and Allergy Hospital, Helsinki University Hospital, Helsinki
2ESiOR Oy, Kuopio
3Janssen-Cilag Oy, Espoo, Finland
4Janssen-Cilag, Sweden
5Infoderm Oy, Tampere
6Vaasa Central Hospital, Vaasa
7Department of Dermatology, Turku University Hospital, Turku
8Department of Dermatology, Kuopio University Hospital and University of Eastern Finland, Kuopio
9HUS Helsinki University Hospital, Lohja Hospital, Lohja
10Department of Dermatology, Mikkeli Central Hospital, Mikkeli
11Department of Dermatology and Allergology, Ålands Central Hospital, Maarianhamina
12Department of Dermatology, Keski-Suomi Central Hospital, Jyväskylä
13PEDEGO Research Unit, University of Oulu, Oulu; Department of Dermatology and Medical Research Center, Oulu University Hospital, Oulu
14Department of Dermatology, Savonlinna Central Hospital, Savonlinna
15Department of Dermatology and Allergology, Kanta-Häme Central Hospital, Hämeenlinna
16Department of Dermatology, Päijät-Häme Central Hospital, Lahti
17Department of Dermatology and Venereology, Kainuu Central Hospital, Kajaani
18Department of Dermatology, Mehiläinen Länsi-Pohja, Kemi
19Department of Dermatology, Tampere University Hospital and Tampere University, Tampere, Finland
Format: article
Version: published version
Access: open
Online Access: PDF Full Text (PDF, 0.7 MB)
Persistent link:
Language: English
Published: Society for Publication of Acta Dermato-Venereologica, 2022
Publish Date: 2022-06-28


Guselkumab treatment outcomes and persistence were assessed in a real-world cohort of Finnish patients with difficult-to-treat plaque psoriasis over a median follow-up of 1 year. Data on 181 patients who initiated guselkumab at the 15 study centres were collected retrospectively from the patient charts. Prior exposure to biologic therapies was common, with 56% and 35% having used at least 1 and 2 biologics, respectively. Median guselkumab treatment duration was 11 months with 21 patients (12%) discontinuing treatment during follow-up. Of 85 patients with a follow-up duration of at least 1 year, 73 (86%) were still on guselkumab at 1 year. Significant improvements during follow-up were seen in the absolute Psoriasis Area and Severity Index (PASI) scores with 32 patients (80%) having absolute PASI ≤ 2 after a 9–14-month treatment. Guselkumab treatment was effective and treatment persistence was high in the nationwide Finnish real-life setting.

see all

Series: Acta dermato-venereologica
ISSN: 0001-5555
ISSN-E: 1651-2057
ISSN-L: 0001-5555
Volume: 102
Article number: adv00631
DOI: 10.2340/actadv.v101.910
Type of Publication: A1 Journal article – refereed
Field of Science: 3121 General medicine, internal medicine and other clinical medicine
Funding: This study was supported by Janssen-Cilag Oy (Finland).
Copyright information: Copyright (c) 2021 Tarja Mälkönen, Pauliina Nuutinen, Taru Hallinen, Erkki Soini, Riikka Nissinen, Christina Wennerstöm, Tapio Rantanen, Johanna H. Hagman, Rauno Harvima, Johanna Höök-Nikanne, Tiina Ilves, Päivi Lintu, Ken Malanin, Iina Soramäki, Kaisa Tasanen, Arja Teho, Katja Vähävihu, Sari Itälinna, Pekka Leinonen, Piia Sarajärvi, Laura Huilaja, Rafael Pasternack. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.